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Abstract
Angiotensin-converting enzyme inhibitors are widely prescribed to regulate blood pressure. High doses of orally
administered perindopril have previously been shown to improve fracture healing in a mouse femur fracture model. In this
study, perindopril was administered directly to the fracture area with the goal of stimulating fracture repair. Three months
after being ovariectomized (OVX), tibial fractures were produced in Sprague–Dawley rats and subsequently stabilized with
intramedullary wires. Perindopril (0.4 mg/kg/day) was injected locally at the fractured site for a treatment period of 7 days.
Vehicle reagent was used as a control. Callus quality was evaluated at 2 and 4 weeks post-fracture. Compared with the
vehicle group, perindopril treatment significantly increased bone formation, increased biomechanical strength, and
improved microstructural parameters of the callus. Newly woven bone was arranged more tightly and regularly at 4 weeks
post-fracture. The ultimate load increased by 66.1 and 76.9% (p,0.01), and the bone volume over total volume (BV/TV)
increased by 29.9% and 24.3% (p,0.01) at 2 and 4 weeks post-fracture, respectively. These findings suggest that local
treatment with perindopril could promote fracture healing in ovariectomized rats.
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Introduction
Osteoporosis is characterized by a reduction in bone mass and
the micro-architectural deterioration of bone tissue, resulting in
bone fragility and an increase in susceptibility to fracture [1,2,3].
Although most anti-osteoporosis drugs have the ability to decrease
the risk of osteoporotic fractures, fractures still occur in patients
undergoing medical treatment. For this reason, the safety and
efficacy of most anti-osteoporosis drugs for fracture healing have
been analyzed to determine whether they should be ceased or
continued after fracture formation [4,5,6,7]. Moreover, it is well
known that anti-osteoporosis drugs also have the ability to
promote fracture healing.
The renin–angiotensin system (RAS) is an endocrine system that
controls body fluids, electrolyte balance, and blood pressure [8]. The
main effector peptide in this system is angiotensin II (Ang II), which
is formed from angiotensin I (Ang I) by the angiotensin-converting
enzyme (ACE), a key molecule in this system. The RAS has been an
important target of antihypertensive drugs [9], particularly ACE
inhibitors [10] and angiotensin receptor blockers (ARBs).
Previous studies have indicated that different components of the
RAS have been found to be synthesized and active in osteoblasts
and osteoclasts [11,12,13]. One study showed that Ang II
encouraged bone resorption in osteoblast and osteoclast co-
cultures [12]. The same effect was found after stimulation with
Ang I and was prohibited by the ACE inhibitor moexiprilat. This
result indicates that Ang II is generated by osteoblasts or
osteoclasts through the conversion of Ang I by ACE. Accordingly,
another study hypothesized that a local RAS in bone might play
an important role in the regulation of bone metabolism [13].
Schurman et al. [14] showed that Ang II suppressed osteoblastic
cell differentiation and bone formation in vitro. This effect was
caused by specific binding of Ang II to the AT1 receptor [15].
Finally, recent studies have also demonstrated the expression of
RAS components in osteoblasts and osteoclasts in vivo [11].
Further evidence for a potential role of the RAS in bone
metabolism is derived from clinical studies. Patients treated with
an ACE inhibitor showed an increased bone mineral density
(BMD) and a reduced fracture risk [16,17].
Up to now, the extensive research on ACE inhibitors has, to a
large extent, been conducted on undisturbed bone; only one study
has been conducted to investigate their effects on fracture healing
[18]. Because perindopril affects bone metabolism locally through
the bone cells, a question that arises is whether local delivery of
this drug to the fracture would work.
The purpose of the present study was to test the hypothesis that
locally-applied perindopril has the ability to promote fracture
healing. In this study, tibial fractures were produced in OVX rats
and subsequently stabilized with intramedullary wires. Perindopril
was injected locally at the fractured site for a treatment period of
days. Callus quality was evaluated at 2 and 4 weeks post-fracture.
Results
An increased body weight was observed in all rats during the
experimental period. No significant difference was found in body
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No infection occurred at the fracture site.
Twelve weeks after either the OVX or sham operation, the
mean tibial BMD value was 0.21460.010 g/cm
2 in the OVX
group, which was significantly lower than the value of
0.26560.015 g/cm
2 in the sham group (P,0.05), confirming
the establishment of the osteoporosis model.
The effect of perindopril on the callus formation
Two weeks post-fracture, radiological analysis showed that the
diameter of the callus was significantly increased in the
OVX+perindopril animals when compared with that of the
OVX+vehicle controls (Fig. 1). However, at 4 weeks, OVX+ve-
hicle controls exhibited an increase in callus diameter when
compared with that of the controls at 2 weeks, whereas the size of
the callus in OVX+perindopril animals was found to have
decreased at this time point when compared with that of the
OVX+perindopril animals at 2 weeks (Fig. 1). Thus, the difference
in callus formation between the two groups observed at 2 weeks
had disappeared by 4 weeks.
The effect of perindopril on the biomechanical properties
The biomechanical properties of fractured tibiae are presented
as ultimate load, energy absorption and stiffness (Table 1). As
expected, the mechanical strength increased with time in both
groups during the evaluation period. However, the fractured tibiae
in the OVX+perindopril group showed significantly higher
mechanical values than those in the OVX+vehicle OVX group,
with the ultimate load increased by 66.1%, energy absorption by
53.2%, and stiffness by 51.7% at 2 weeks post-fracture (p,0.01).
Similarly, the mechanical values of the OVX+perindopril group
were increased compared with those of the OVX+vehicle group at
4 weeks post-fracture, with the ultimate load increased by 76.9%,
energy absorption by 93.7% and stiffness by 63.9% (p,0.01).
The OVX+perindopril group showed more cartilage
formation and greater newly forming trabeculae than the
OVX+vehicle animals
At 2 weeks post-fracture, callus formation in the periosteum and
endochondral ossification in the soft callus were recognized in both
groups. Cartilaginous callus formation was visible in the
OVX+perindopril animals, whereas less cartilage formation was
visible in the OVX+vehicle animals. At 4 weeks post-fracture,
compared with OVX+vehicle callus zones, new woven bone in
OVX+perindopril animals arranged more tightly and regularly
(Fig. 2). The OVX+perindopril group showed greater and denser
newly forming trabeculae than the OVX+vehicle animals
(Table 2). There was no sign of malignant transformations in
any of the cell types in the callus areas in the perindopril-treated
groups throughout the study period (Fig. 2).
The administration of perindopril significantly improved
the histomorphometric parameters in the
ovariectomized rat tibiae
From the three-dimensional reconstruction of the bony callus, a
greater amount of bony callus was found in the OVX+perindopril
group than in the OVX+vehicle group at both 2 and 4 weeks post-
fracture, which demonstrates the anabolic effect of perindopril
during the early period of fracture healing (Table 2). The fracture
gap in both groups could be clearly seen at 2 weeks post-fracture.
At 4 weeks, the fracture gap could be clearly observed in the
OVX+vehicle group, while it was nearly invisible in the
OVX+perindopril group (Fig. 3).
The results of the fractured tibiae (Table 2) from the Micro-CT
evaluation were expressed as BV/TV and CsAr. At 2 weeks post-
fracture, perindopril treatment significantly increased the values of
BV/TV by 29.9% and CsAr by 43.8% (p,0.01) compared to the
OVX+vehicle group. A similar trend was found at 4 weeks post-
fracture, with BV/TV increased by 24.3% and CsAr by 55.2%
(p,0.01). These quantitative results show that the administration
of perindopril significantly improved the histomorphometric
parameters in the ovariectomized rat tibiae.
Discussion
In the current study, the results from radiological, biomechan-
ical, histological, and micro-CT evaluations demonstrate that
perindopril can promote fracture healing in OVX rats when
injected subcutaneously into tissue in close proximity to the
Figure 1. Radiological analysis of callus diameter in relation to
the diameter of the tibia at the fracture site after perindopril
treatment. All data are given as mean 6 s.d. *P,0.05 versus
corresponding values of the vehicle-treated controls. # P,0.05 versus
corresponding values of specimens at 2 weeks post-fracture (n=6 per
group).
doi:10.1371/journal.pone.0033228.g001
Table 1. Biomechanical parameters in the fractured site of
tibiae.
OVX+vehicle OVX+perindopril
2 weeks post-fracture (n=6 per group)
Ultimate load (N) 12.462.1 20.663.2**
Energy absorption (mJ) 7.961.4 12.162.8**
Stiffness (N/mm) 89.267.5 135.3612.6**
4 weeks post-fracture (n=6 per group)
Ultimate load (N) 21.663.2 38.263.7**
Energy absorption (mJ) 14.262.1 27.563.4**
Stiffness (N/mm) 131.169.5 214.9617.6**
Data are mean followed by standard deviation.
**P,0.01 vs OVX+vehicle group.
doi:10.1371/journal.pone.0033228.t001
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treatment induced increased callus, improved the callus micro-
structure and enhanced healing strength, and accelerated fracture
healing compared to the untreated OVX group. To our
knowledge, this is the first experimental study to demonstrate that
locally applied perindopril can promote fracture healing in OVX
rats, thereby confirming our hypothesis.
To the best of our knowledge, mechanical rehabilitation of the
fractured bone is the key goal of fracture healing in clinics.
Previous studies have indicated that osteoporotic fracture healing
is a closely regulated process of regaining the textural geometry
and mechanical features of the fractured bone [1,25,26,27,28]. For
this reason, mechanical rehabilitation is not the culminate
completion of fracture healing; geometrical and histological
restoration are also important for the completion of natural
fracture healing. In this study, we evaluated the effect of
perindopril on the biomechanical features of the bony callus,
and we also estimated its effect on the microstructure of the callus.
The findings demonstrated that the mechanical parameters of the
callus in the perindopril group were higher than those in the
control group based on three-point bending tests. In addition, the
microstructure of the callus in the perindopril group was superior
to that of the control group as shown by micro-CT based
quantitative and qualitative analysis and HE staining. Accordingly,
these findings indicate that perindopril is beneficial for osteopo-
rotic fracture healing by promoting the mechanical properties of
the callus and facilitating the microstructure rehabilitation of the
bony callus.
The ACE is a major constituent of the RAS, generating Ang II
as the main effector molecule. Many experiments have indicated
that Ang II can be synthesized by osteoblastic cells through the
ACE and that Ang II affects osteoblastic cell functions through
Table 2. Micro-CT based histomorphometry of the fractured
tibiae.
OVX+vehicle OVX+perindopril
2 weeks post-fracture (n=6 per
group)
BV/TV(%) 39.864.5 51.765.7**
CsAr(mm
2)1 7 . 6 62.9 25.364.7**
4 weeks post-fracture (n=6 per
group)
BV/TV(%) 61.765.1 76.766.2**
CsAr(mm
2)1 5 . 4 63.1 23.962.5**
BV/TV bone volume over total volume, CsAr average cross-sectional area.
Data are mean followed by standard deviation.
**p,0.01 vs OVX+vehicle group.
doi:10.1371/journal.pone.0033228.t002
Figure 3. Micro-CT images from coronal cut aways via the
central part of the 3-D reconstructions of fractured tibia at 2 (a,
b) and 4 (c, d) weeks post-fracture (n=6 per group); a, c for the
OVX+vehicle group and b, d for the OVX+perindopril group.
BC, bony callus; FL, fracture line.
doi:10.1371/journal.pone.0033228.g003
Figure 2. Histological presentations of OVX+vehicle (a, c, e, g)
and OVX+perindopril (b, d, f, h) callus zones at 2 (a, b, e, f) and
4 (c, d, g, h) weeks post-fracture (n=6 per group). Original
magnifications: e, f: 610; g, h: 620; c, d: 6100; a, b: 6200. Cg, cartilage
callus; Wb, woven bone.
doi:10.1371/journal.pone.0033228.g002
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effects mainly through two receptors, the AT1 and AT2 receptors.
Ang II has a large number of biological effects in different tissues
and influences inflammation, angiogenesis, cell proliferation, cell
differentiation and apoptosis [29]. Therefore, the RAS has been
demonstrated to significantly influence tissue remodeling in
various tissues [29]. Both AT1 and AT2 receptors induce
apoptosis in different cell types [29,30,31]. ACE inhibition has
also been shown to decrease apoptosis in various tissues
[30,32,33].
Because ACE inhibitors are widely used in cardiovascular
medicine, it is important to determine how these drugs may
interfere with bone homeostasis. Clinical studies have shown that,
under normotensive and hypertensive conditions, ACE inhibition
significantly increased BMD, especially in the elderly [17]. Thus,
normotensive patients with a I/I polymorphism and low ACE
activity also had an increased BMD [16].
The unbalanced bone turnover is caused by extraordinary bone
resorption and impaired bone formation, which could produce
adverse effects on fracture healing in osteoporotic subjects.
Anticatabolic drugs (i.e., bisphosphonates, estrogen, and salmon
calcitonin) and anabolic agents (such as parathyroid hormone)
have been used to treat osteoporotic fractures. Anticatabolic drugs
based on the inhibition of bone resorption can result in an
increased callus volume, BMD and biomechanical strength during
the early healing period, and they might delay callus remodeling
[34,35]. Parathyroid hormone (1–34) has been demonstrated to
improve cancellous bone healing at the site of an osteotomy
[24,36]. Thus, it is reasonable to study the effect of perindopril on
fracture healing because the dual effects of the RAS on inhibiting
bone resorption and promoting bone formation have been verified
in vitro and in vivo [11,37,38,39].
In a previous study, the effects of perindopril on bone fracture
healing were examined. A femur fracture model was made and
then stabilized with marrow nailing in a murine female fracture
model, and perindopril was administrated systemically at a high
dose (3 mg/kg/day) [18]. At 2 and 5 weeks after fracture,
perindopril-treated animals showed significantly greater periosteal
callus formation compared with controls. This study also
demonstrated a greater torque to failure and a higher torsional
stiffness after 2 and 5 weeks in perindopril-treated animals. In this
study, perindopril was administered subcutaneously to the fracture
site at a relatively lower dose, and increased callus area and
enhanced fracture strength were found at 2 weeks post-fracture.
Meanwhile, we also found increased fracture strength in the
perindopril-treated fractures at 4 weeks post-fracture when the
difference in callus size disappeared.
There are several limitations in this study. First, our fracture
model was established based on a surgical osteotomy in contrast
with a closed fracture model, the latter of which better describes
common clinical fractures. However, this model enabled us to
make a consistent fracture line, which is essential for making
reliable and accurate evaluations. Second, perindopril was
delivered by an invasive approach, which has the possibility of
increasing the risk of infection. This problem can be solved if the
drug is administered via an adequate carrier, delivering a local
continuous dose. Nevertheless, the current study revealed that it
might be possible to use ACE inhibitors to improve the healing of
osteoporotic fractures.
In summary, our data show that local treatment with
perindopril at a dose of 0.4 mg/kg/day promotes fracture healing
of proximal tibiae in an ovariectomized rat model within a 4-week
treatment period. Compared with the untreated OVX group, the
perindopril treatment group showed an increase in callus quality
and biomechanical strength, as well as improved callus micro-
structural parameters, without a negative effect on the natural
fracture healing process. These animal fracture data suggest that
the local application of perindopril could be a new option to
improve the quality of fracture healing.
Materials and Methods
Animals
A total of 86, 3-month-old female Sprague–Dawley rats
(purchased from the Experimental Animal Center of The Fourth
Military Medical University, Xi’An, China) with an average
weight of 250 g at the beginning of the study were used. The rats
were maintained at 20uC on a 12-h light/dark cycle with free
access to water and rat food containing 0.46% calcium and 0.38%
phosphorus. All experimental procedures in animals were
approved by the Ethics in Animal Research Committee of the
Fourth Military Medical University (permission code
2010C00843).
Fracture surgery
Three months after being ovariectomized (OVX) (n=76) or
sham-operated (n=10) according to previous studies [19],
osteopenia in the OVX rats was diagnosed using the Lunar iDXA
scanner (GE Healthcare Lunar, USA) with the hand-regional
high-resolution and small-animal scan mode as previously
described [1]. The region of interest was defined as a longitudinal
rectangle that was adjusted to cover the total right tibial area.
General anesthesia for all operative procedures was achieved with
intraperitoneal injections of 10% chloral hydrate (3.3 ml/kg).
Then, in all animals, a simple transverse open fracture model was
made in the proximal one-third of the right tibia, as previously
reported [19,20]. Briefly, a 2-cm longitudinal incision was made
on the medial side of the knee joint. After careful dissection of
subcutaneous tissues, a transverse osteotomy was made at the
proximal one-third of the proximal tibia. Subsequently, the patella
was deflected laterally, and a hole was drilled in the anterior
intercondylar area. Then, the fracture fragments were contacted,
and a stainless steel wire (1.0 mm in diameter) was inserted
through a hole across the fracture ends. Soft tissues were sutured,
and the animals received an intramuscular antibiotic and analgesic
injection for three postoperative days. Each animal received
antibiotics (penicillin, 0.80 million units, IM, BID) for three days
postoperatively. Unrestricted activity was allowed after the
anesthesia resolved. Among the 76 animals present at the
beginning of the study, 4 rats died due to anesthesia and surgical
trauma. The remaining 72 rats were randomly divided into four
groups (n=18 for each group).
Pharmaceutical intervention
The perindopril powder was dissolved in PEG-400 to obtain a
concentration of 4 mg/ml. A vehicle without perindopril was also
prepared. Perindopril or vehicle drugs were injected subcutane-
ously into the fracture site once on the day of fracture and once a
day for 7 days thereafter. Each injection contained 0.4 mg/kg of
perindopril in the experimental group and an equal volume (about
30–50 ml) of vehicle solution in the vehicle groups. In this study,
perindopril was injected via the method described previously [20].
Radiography analysis
At the end of the 2- and 4-week post-fracture observation
periods, the rats were anesthetized (10% chloral hydrate, same
dosage as above), and ventro-dorsal radiographs of the healing
tibiae were taken. X-rays were taken by a DMR+ Mo target
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diameter was measured in relation to the tibia diameter (%).
Biomechanical analysis
For biomechanical analysis, the right tibiae were resected and
carefully freed from soft tissue, and the intramedullary pins were
removed. The bones (n=6 per group at each time point) were
then subjected to a three-point bending test using a commercial
material testing system (Instron 4302; Instron, Norwood, MA,
USA) as previously reported [20,21]. Briefly, the tibia was placed
in the material testing machine on two supports separated by a
distance of 1.5 mm, and the testing area was defined as the central
part of the callus. A compression load was applied at a rate of
2.0 mm/min until breakage. From the load–deflection curve
recorded by a connected computer, the ultimate load at failure (N;
maximum force that the tibia could bear), total energy absorption
(MJ; energy absorbed by the tibia during compression), and
stiffness (N/mm; slope of the load-deflection curve from the linear
part) were calculated.
Histological analysis
Immediately after animals were killed, the right tibia was
harvested without damaging the periosteum. Extreme care was
taken to not traumatize the callus. After the steel wire had been
withdrawn, the middle part of the tibia that contained the callus
was cut. Specimens (n=6 per group at each time point) were then
fixed in 4% buffered formaldehyde for approximately 48 h at
room temperature and decalcified in ethylene diaminetetra-acetic
acid (EDTA, 0.5 mol/L, PH 7.4) for approximately 4 weeks. The
EDTA was refreshed every 3 days until a fine needle could easily
be inserted into the bone. Decalcified specimens were then
washed, dehydrated in gradient alcohol, embedded in paraffin
wax, and cut into 4-mm-thick sections along the longitudinal plane
of the tibia. The sections were stained with hematoxylin and eosin
and another section was stained with a modified Ponceau
trichrome stain, and the slices were examined qualitatively under
light microscopy (Leica Instruments GmbH, Germany) with
digital cameras.
Micro-CT analysis
For the micro-CT scan, a desktop micro-CT system (GE
Healthcare, USA) was employed. All right tibiae (n=6 per group
at each time point) were prepared by cutting them into 10-mm-
long blocks with the callus included and then storing them in 70%
ethanol. These specimens were secured with a foam board to
prevent them from shifting during scanning at a voltage of 55 kV
and a current of 145 mA. Then, 16.4-mm-thick coronal images
were reconstructed to evaluate longitudinal fracture callus
features. The scanned zone included the original cortical
diaphyseal bone and the entire diameter of the periosteal and
endosteal callus. Two-dimensional CT images were reconstructed
in 102461024-pixel matrices using a standard convolution back-
projection procedure. Images were stored in 3-D arrays with an
isotropic voxel size of 16.4 mm. A constrained 3-D Gaussian filter
was used to partly suppress the noise in the volumes. The high and
low radio-opacity mineralized tissues were differentially segmented
by a two-level global thresholding procedure [21,22]. The callus
volume of interest (VOI) was defined as new-formed bone tissues;
the medullary canal volume and the original bone tissue were
excluded from evaluation in accordance with previous reports
[23,24]. After segmentation, the following parameters were
quantified within the VOI: bone volume over total volume (BV/
TV) and average cross-sectional area (CsAr).
Statistical analysis
All values are expressed as the mean with their standard
deviation (mean6S.D.) in the text and the tables. Statistical
analyses were conducted using the statistics package SPSS 13.0
(SPSS, Chicago, IL, USA). Differences among treatment groups
were tested by one-way analysis of variance (ANOVA). If
significant differences were indicated, differences between the
means of two groups were tested by Fisher’s protected least
significant difference (PLSD). Differences were considered signif-
icant for p,0.05 and highly significant for p,0.01.
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